Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Social media and AI chatbots face gaps in supporting vulnerable users

Two new studies highlight how communication gaps can complicate efforts to protect vulnerable users of technologies such as social media and AI chatbots. Researchers will present the work at the 29th ACM Conference on Computer-Supported Cooperative Work and Social Computing (CSCW 2026), held October 1–14 in Salt Lake City.

6 Oct 2026

Existing drug could target neuroinflammation in Alzheimer's patients

Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer's could be targeted with an existing drug thanks to new research that shows it can work in brain cells.

5 Oct 2026

Novel 'speech clock' can estimate a person's chronological age

A large study shows that machine-learning clocks based on speech can estimate chronological age and may also offer a window into brain aging, biological aging, cognitive health, cumulative burden, and dementia.

30 Sep 2026

Neck lymph node removal surgery may disrupt brain waste clearance

Surgery to remove lymph nodes in the neck may interfere with cerebrospinal fluid (CSF) drainage from the brain, contributing to cognitive impairment, according to new multicenter research led by Weill Cornell Medicine scientists.

29 Sep 2026

New antibody treatment blocks immune response to prevent Alzheimer's damage

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer's disease, in which twisted clumps of a protein called tau accumulate in the brain.

28 Sep 2026

Insomnia linked to increased risk of stroke and hospital admissions

Insomnia is not only associated with poor sleep and reduced daytime functioning, but may also be an indicator of increased health risks.

28 Sep 2026

Study links insomnia to higher stroke and hospitalization risks

Insomnia is associated with a 26% higher risk of stroke and 28% higher odds of hospital admission, according to new research in Sleep Medicine Reviews. The researchers say the findings support recognizing insomnia as an important marker of brain, mental and general health.

28 Sep 2026

Mathematical models simulate how common metals influence Alzheimer's disease

What can mathematics reveal about Alzheimer's disease? Mississippi State Associate Professor Shantia Yarahmadian is using mathematical modeling to examine how common metals may influence a protein that forms plaque associated with Alzheimer's disease-and how potential therapies could alter these processes.

25 Sep 2026

Blood proteins may help monitor Alzheimer’s treatment response

Patients with early symptoms of Alzheimer's disease may be prescribed anti-amyloid therapy, which can help clear the sticky clumps of amyloid protein in the brain that characterize Alzheimer's.

25 Sep 2026

Mount Sinai researchers discover how Alzheimer's gene damages blood vessels

Mount Sinai researchers have identified how APOE4, the strongest genetic risk factor for Alzheimer's disease, damages the brain's blood vessels and promotes the buildup of abnormal proteins linked to neurodegenerative disease.

24 Sep 2026

Chronic stress and social support affect how cognitive abilities change with age

Chronic stress and perceived social support may play a role in how memory and thinking abilities change with age, according to a new study led by researchers at Wake Forest University School of Medicine.

24 Sep 2026

Lund University gets $19.4 million grant for Alzheimer’s blood test

Alzheimer’s researcher Sebastian Palmqvist has been awarded USD 19.4 million (SEK 190 million) from the US National Institutes of Health (NIH), through its National Institute on Aging (NIA).

24 Sep 2026

PsychAD studies map molecular mechanisms across major brain disorders

Research led by Mount Sinai scientists within the PsychAD Consortium, a large-scale, multidisciplinary initiative launched in 2019 with support from the National Institute on Aging (NIA), is featured in a landmark collection of nine papers published across the Nature family of journals that maps the molecular mechanisms underlying Alzheimer's disease, Parkinson's disease, schizophrenia, and other brain disorders.

23 Sep 2026

Menopause leaves a blood protein signature linked to brain aging and Alzheimer’s risk

Researchers identified a 16-protein blood signature associated with menopause that tracked more strongly with reproductive hormones than chronological age and was largely replicated in an independent UK Biobank cohort. Higher menopause proteomic scores were also associated with less favorable proteomic aging estimates and poorer cognitive outcomes in older women, including incident Alzheimer’s dementia, although the observational evidence does not establish causality.

23 Sep 2026

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

23 Sep 2026

New 3D lipid atlas maps the chemistry of mouse brains

The brain is often described in terms of cells and wiring. However, much of it is made of lipids that form the membranes of neurons, wrap nerve fibers with myelin, and help brain cells send and receive signals.

23 Sep 2026

People with dementia can participate in research without experiencing significant burden

A multidisciplinary study conducted at the University of Eastern Finland has shown that people with dementia and their caregivers can participate in demanding research without experiencing a significant burden.

23 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

New brain circuit discovery offers hope for panic disorder treatments

Our survival depends on brains that constantly search for danger and, if found, stay alert until it has passed.

21 Sep 2026

Active form of meprin-β protein increases in people with Alzheimer’s disease

A team from the Altered Molecular Mechanism in Alzheimer's Disease and Dementia laboratory, led by Javier Sáez Valero, a researcher at the Institute for Neurosciences (IN), a joint centre of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), has identified increased levels of the protein meprin-β in the brain and cerebrospinal fluid of people with Alzheimer's disease.

21 Sep 2026